Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

-- Findings Presented at AMCP Nexus 2025 Annual Meeting --

BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and economic benefits of EXPAREL^® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting taking place October 27–30 in National Harbor, Maryland.